Literature DB >> 12515570

Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.

Brian J Cohen1.   

Abstract

Cost-utility analysis (CUA) is a technique that can potentially be used as a guide to allocating healthcare resources so as to obtain the maximum health benefits possible under a given budget constraint. However, it is not clear that current practice captures societal preferences regarding health benefits. In analyses of healthcare interventions providing survival benefits, the market rate of interest is the sole empirical variable that reflects societal preferences. This approach is based on the assumptions that: (i) healthcare interventions should be ranked using cost-effectiveness (CE) ratios; (ii) the discount rate for costs in CUA should be equal to that used in cost-benefit analysis (CBA); (iii) the discount rate in CBA should be the market rate of interest on long-term government bonds; and (iv) the Keeler-Cretin paradox is applicable to CUA of healthcare interventions, so that the discount rate for benefits in CUA should be set equal to the discount rate for costs. This approach ignores a fundamental difference between CBA and CUA, namely that CUA assumes that a budget constraint has been specified prior to the analysis. It starts with the assumption that a given amount of funds have been withdrawn from the economy to fund healthcare, so there is no opportunity cost to consider. For that reason, the principles on which the choice of discount rate rests differ in the two techniques. Furthermore, use of CE ratios to rank interventions assumes that the budget constraint can be expressed as a single constraint. But healthcare budgets are multiyear budgets that are roughly constant from year to year. A more realistic model would involve multiple constraints and would require linear programming for solution. This can be reduced to a series of single constraints, thereby allowing use of the simpler CE ratio approach, if we assume that the budget being allocated is intended for one cohort at a time, i.e. all people for whom a new funding decision must be made in a given year. In general, we assume that future cohorts will be allotted comparable funding. However, the Keeler-Cretin paradox depends on the assumption that cohorts are competing with each other for resources, and is therefore not applicable to CUA of healthcare. Other approaches are therefore needed to assign utilities to healthcare interventions providing survival benefits. Methods should be developed that allow analyses to reflect a range of philosophical approaches through sensitivity analysis.

Entities:  

Mesh:

Year:  2003        PMID: 12515570     DOI: 10.2165/00019053-200321020-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.

Authors:  D Meltzer; M Johannesson
Journal:  Med Decis Making       Date:  1999 Oct-Dec       Impact factor: 2.583

Review 2.  Methodological limitations of cost-effectiveness analysis in health care: implications for decision making and service provision.

Authors:  J Raftery
Journal:  J Eval Clin Pract       Date:  1999-11       Impact factor: 2.431

3.  The quality of reporting in published cost-utility analyses, 1976-1997.

Authors:  P J Neumann; P W Stone; R H Chapman; E A Sandberg; C M Bell
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

Review 4.  Weighing the economic evidence: guidelines for critical assessment of cost-effectiveness analyses.

Authors:  S D Ramsey; S D Sullivan
Journal:  J Am Board Fam Pract       Date:  1999 Nov-Dec

5.  Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.

Authors:  A Stewart; J K Schmier; B R Luce
Journal:  Am Heart J       Date:  1999-05       Impact factor: 4.749

Review 6.  Understanding cost effectiveness: a detailed review.

Authors:  A F Smith; G C Brown
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

7.  Clinical decision making: from theory to practice. Cost-effectiveness analysis. A conversation with my father.

Authors:  D M Eddy
Journal:  JAMA       Date:  1992-03-25       Impact factor: 56.272

Review 8.  Assigning values to intermediate health states for cost-utility analysis: theory and practice.

Authors:  B J Cohen
Journal:  Med Decis Making       Date:  1996 Oct-Dec       Impact factor: 2.583

Review 9.  Discounting in the economic evaluation of health care interventions.

Authors:  M Krahn; A Gafni
Journal:  Med Care       Date:  1993-05       Impact factor: 2.983

10.  Discounting in cost-effectiveness research.

Authors:  T G Ganiats
Journal:  Med Decis Making       Date:  1994 Jul-Sep       Impact factor: 2.583

View more
  4 in total

Review 1.  Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.

Authors:  Jasper M Bos; Philippe Beutels; Lieven Annemans; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Discounting health effects in pharmacoeconomic evaluations: current controversies.

Authors:  J M Bos; Maarten J Postma; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies.

Authors:  Li Fan; Wen-Chao Liu; Yan-Jun Zhang; Jun Ren; Bo-Rong Pan; Du-Hu Liu; Yan Chen; Zhao-Cai Yu
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

4.  Campylobacter control measures in indoor broiler chicken: critical re-assessment of cost-utility and putative barriers to implementation.

Authors:  J G Pitter; Z Vokó; Á Józwiak; A Berkics
Journal:  Epidemiol Infect       Date:  2018-06-27       Impact factor: 4.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.